Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01815736
Registration number
NCT01815736
Ethics application status
Date submitted
19/03/2013
Date registered
21/03/2013
Date last updated
13/04/2021
Titles & IDs
Public title
Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
Query!
Scientific title
A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects
Query!
Secondary ID [1]
0
0
2012-005114-20
Query!
Secondary ID [2]
0
0
GS-US-292-0109
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
HIV
0
0
Query!
HIV Infections
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Acquired immune deficiency syndrome (AIDS / HIV)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - E/C/F/TAF
Treatment: Drugs - E/C/F/TDF
Treatment: Drugs - EFV/FTC/TDF
Treatment: Drugs - RTV
Treatment: Drugs - ATV
Treatment: Drugs - FTC/TDF
Treatment: Drugs - COBI
Experimental: E/C/F/TAF - Randomized Phase: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) for up to 96 weeks.
Extension Phase: After completing 96 weeks of randomized treatment, all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.
Active Comparator: Stay on Baseline Treatment Regimen (SBR) - Randomized Phase: Participants stayed on their baseline emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)-containing regimen E/C/F/TDF; efavirenz (EFV)/FTC/TDF; ritonavir (RTV)-boosted atazanavir (ATV)+FTC/TDF; or cobicistat (COBI-boosted ATV+FTC/TDF) administered according to prescribing information for up to 96 weeks.
Extension Phase: After completing 96 weeks of randomized treatment (SBR), all participants will be given the opportunity to receive open-label E/C/F/TAF until it becomes commercially available, or until Gilead elects to terminate the development of E/C/F/TAF.
Treatment: Drugs: E/C/F/TAF
150/150/200/10 mg FDC tablet administered orally once daily
Treatment: Drugs: E/C/F/TDF
150/150/200/300 mg FDC tablet administered orally once daily
Treatment: Drugs: EFV/FTC/TDF
600/200/300 mg FDC tablet administered orally once daily
Treatment: Drugs: RTV
100 mg tablet administered orally once daily
Treatment: Drugs: ATV
300 mg capsule administered orally once daily
Treatment: Drugs: FTC/TDF
200/300 mg tablet administered orally once daily
Treatment: Drugs: COBI
150 mg tablet administered orally once daily
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48
Query!
Assessment method [1]
0
0
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Query!
Timepoint [1]
0
0
Week 48
Query!
Secondary outcome [1]
0
0
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Query!
Assessment method [1]
0
0
Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. BMD is calculated as grams per square centimeter (g/cm^2); the mean (SD) percentage change is presented.
Query!
Timepoint [1]
0
0
Baseline; Week 48
Query!
Secondary outcome [2]
0
0
Percent Change From Baseline in Spine BMD at Week 48
Query!
Assessment method [2]
0
0
Spine BMD was assessed by DXA scan. BMD is calculated as g/cm^2; the mean (SD) percentage change is presented.
Query!
Timepoint [2]
0
0
Baseline; Week 48
Query!
Secondary outcome [3]
0
0
Change From Baseline in Serum Creatinine at Week 48
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline; Week 48
Query!
Secondary outcome [4]
0
0
Change From Baseline in the Overall EFV-related Symptom Assessment Score at Week 48
Query!
Assessment method [4]
0
0
The mean (SD) change of the overall EFV-related symptom assessment score is presented. The overall symptom score (ranging from 0 to 20) is the sum of the individual symptom scores ranging from 0 (no symptoms) to 4 (most severe symptoms) from the 5 EFV-related symptom assessments (dizziness, trouble sleeping, impaired concentration, sleepiness, and abnormal or vivid dream). A negative change from baseline indicates improvement.
EFV-Related Symptom Analysis Set: participants who received EFV/FTC/TDF as prior treatment, received at least 1 dose of study drug, and completed EFV-related symptom assessments at the baseline visit and at least 1 postbaseline visit.
Query!
Timepoint [4]
0
0
Baseline; Week 48
Query!
Secondary outcome [5]
0
0
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96
Query!
Assessment method [5]
0
0
The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Query!
Timepoint [5]
0
0
Week 96
Query!
Secondary outcome [6]
0
0
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 48
Query!
Assessment method [6]
0
0
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Query!
Timepoint [6]
0
0
Week 48
Query!
Secondary outcome [7]
0
0
Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Week 96
Query!
Assessment method [7]
0
0
The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Query!
Timepoint [7]
0
0
Week 96
Query!
Secondary outcome [8]
0
0
Change From Baseline in Cluster Determinant 4 (CD4) Cell Count at Week 48
Query!
Assessment method [8]
0
0
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Query!
Timepoint [8]
0
0
Baseline; Week 48
Query!
Secondary outcome [9]
0
0
Change From Baseline in CD4 Cell Count at Weeks 96
Query!
Assessment method [9]
0
0
The analysis of CD4 cell count included values up to 1 day after the last dose date of randomized study drug.The change from baseline in CD4 cell count for the full analysis set was based on observed data (ie, Missing = Excluded) for the total and by the prior treatment regimen.
Query!
Timepoint [9]
0
0
Baseline; Week 96
Query!
Eligibility
Key inclusion criteria
Key
- Ability to understand and sign a written informed consent form, which must be obtained
prior to initiation of study procedures
- Currently receiving antiretroviral therapy consisting of E/C/F/TDF, EFV/FTC/TDF,
RTV+ATV+FTC/TDF, or COBI+ATV+FTC/TDF for = 6 consecutive months preceding the final
visit in their earlier study
- Completion of the Week 144 visit in studies GS-US-236-0102, GS-US-236-0103,
GS-US-216-0114, or completion of the Week 96 visit in study GS-US-264-0110 (only
participants on an EFV-based regimen), or completion of studies GS-US-236-0104,
GS-US-216-0105
- Plasma human immunodeficiency virus type 1-ribonucleic acid (HIV-1 RNA) concentrations
at undetectable levels for at least 6 consecutive months prior to the screening visit
and have HIV RNA < 50 copies/mL at the screening visit
- Normal echocardiograph (ECG)
- Estimated glomerular filtration rate (GFR) = 50 mL/min according to the
Cockcroft-Gault formula for creatinine clearance
- Hepatic transaminases (aspartate aminotransferase [AST] and alanine aminotransferase
[ALT]) = 5 × upper limit of the normal range (ULN)
- Direct bilirubin = 1.5 x ULN
- Adequate hematologic function
- Serum amylase = 5 × ULN
- Females of childbearing potential must agree to utilize highly effective contraception
methods or be non-heterosexually active or practice sexual abstinence from screening
throughout the duration of study treatment and for 12 weeks following the last dose of
study drug if receiving EFV/FTC/TDF regimen, and 30 days for those assigned to all
other regimens.
- Female participants who utilize hormonal contraceptive as one of their birth control
methods must have used the same method for at least three months prior to study dosing
- Female participants who have stopped menstruating for = 12 months but do not have
documentation of ovarian hormonal failure must have a serum follicle stimulating
hormone (FSH) level at screening within the post-menopausal range based on the Central
Laboratory reference range
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- A new acquired immunodeficiency syndrome (AIDS)-defining condition diagnosed within
the 30 days prior to screening
- Hepatitis B surface antigen position
- Hepatitis C antibody positive
- Participants experiencing decompensated cirrhosis
- Females who are breastfeeding
- Positive serum pregnancy test
- Have an implanted defibrillator or pacemaker
- Current alcohol or substance use judged by the Investigator to potentially interfere
with subject study compliance
- History of malignancy within the past 5 years or ongoing malignancy other than
cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous
squamous carcinoma
- Active, serious infections (other than HIV-1 infection) requiring parenteral
antibiotic or antifungal therapy within 30 days prior to baseline
- Any other clinical condition or prior therapy that, in the opinion of the
Investigator, would make the subject unsuitable for the study or unable to comply with
dosing requirements
- Participation in any other clinical trial without prior approval from the sponsor is
prohibited while participating in this trial
- Participants receiving ongoing therapy with drugs not to be used with elvitegravir
(EVG), COBI, FTC, TDF, ATV, RTV, EFV, and TAF or participants with any known allergies
to the excipients of E/C/F/TDF, E/C/F/TAF, EFV/FTC/TDF, ATV, COBI, RTV, or FTC/TDF
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
27/03/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1443
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
East Sydney Doctors - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Holdsworth House Medical practice - Darlinghurst
Query!
Recruitment hospital [3]
0
0
St Vincent's Hospital, Sydney - Darlinghurst
Query!
Recruitment hospital [4]
0
0
Taylor Square Private Clinic - Darlinghurst
Query!
Recruitment hospital [5]
0
0
Albion Street Centre - Surry Hills
Query!
Recruitment hospital [6]
0
0
Melbourne Sexual Health Clinic - Carlton
Query!
Recruitment hospital [7]
0
0
Alfred Hospital - Melbourne
Query!
Recruitment hospital [8]
0
0
Northside Clinic - Melbourne
Query!
Recruitment hospital [9]
0
0
Prahran Market Clinic - South Yarra
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2010 - Surry Hills
Query!
Recruitment postcode(s) [3]
0
0
3053 - Carlton
Query!
Recruitment postcode(s) [4]
0
0
3004 - Melbourne
Query!
Recruitment postcode(s) [5]
0
0
3068 - Melbourne
Query!
Recruitment postcode(s) [6]
0
0
3141 - South Yarra
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Georgia
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Hawaii
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Illinois
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Minnesota
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Missouri
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Mexico
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Texas
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Virginia
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Washington
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Wisconsin
Query!
Country [27]
0
0
Austria
Query!
State/province [27]
0
0
Graz
Query!
Country [28]
0
0
Austria
Query!
State/province [28]
0
0
Vienna
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Brussels
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Ghent
Query!
Country [31]
0
0
Brazil
Query!
State/province [31]
0
0
Rio de Janeiro
Query!
Country [32]
0
0
Brazil
Query!
State/province [32]
0
0
Santo Andre
Query!
Country [33]
0
0
Brazil
Query!
State/province [33]
0
0
Sao Paulo
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
British Columbia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Manitoba
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Quebec
Query!
Country [38]
0
0
Denmark
Query!
State/province [38]
0
0
Copenhagen
Query!
Country [39]
0
0
Dominican Republic
Query!
State/province [39]
0
0
Santo Domingo
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Lyon
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Nantes
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Nice
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Paris
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Tourcoing
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Berlin
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Bonn
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Duesseldorf
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Frankfurt am Main
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Freiburg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Hamburg
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Köln
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
München
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Milano
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Milan
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Rome
Query!
Country [56]
0
0
Italy
Query!
State/province [56]
0
0
Torino
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Guadalajara
Query!
Country [58]
0
0
Netherlands
Query!
State/province [58]
0
0
Amsterdam
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Rotterdam
Query!
Country [60]
0
0
Portugal
Query!
State/province [60]
0
0
Lisbon
Query!
Country [61]
0
0
Portugal
Query!
State/province [61]
0
0
Porto
Query!
Country [62]
0
0
Puerto Rico
Query!
State/province [62]
0
0
San Juan
Query!
Country [63]
0
0
Spain
Query!
State/province [63]
0
0
Barcelona
Query!
Country [64]
0
0
Spain
Query!
State/province [64]
0
0
Madrid
Query!
Country [65]
0
0
Spain
Query!
State/province [65]
0
0
Sevilla
Query!
Country [66]
0
0
Sweden
Query!
State/province [66]
0
0
Stockholm
Query!
Country [67]
0
0
Switzerland
Query!
State/province [67]
0
0
Bern
Query!
Country [68]
0
0
Switzerland
Query!
State/province [68]
0
0
Lausanne
Query!
Country [69]
0
0
Switzerland
Query!
State/province [69]
0
0
Zürich
Query!
Country [70]
0
0
Thailand
Query!
State/province [70]
0
0
Bangkok
Query!
Country [71]
0
0
Thailand
Query!
State/province [71]
0
0
Chiang Mai
Query!
Country [72]
0
0
Thailand
Query!
State/province [72]
0
0
Khon Kaen
Query!
Country [73]
0
0
United Kingdom
Query!
State/province [73]
0
0
Brighton
Query!
Country [74]
0
0
United Kingdom
Query!
State/province [74]
0
0
London
Query!
Country [75]
0
0
United Kingdom
Query!
State/province [75]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Gilead Sciences
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of this study is to evaluate the non-inferiority of switching to a
tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining
tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically
suppressed HIV-infected participants as determined by having HIV-1 RNA < 50 copies/mL at Week
48.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01815736
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gilead Study Director
Query!
Address
0
0
Gilead Sciences
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01815736
Download to PDF